Publikationen von Mirjam Koker
Alle Typen
Zeitschriftenartikel (15)
2015
Zeitschriftenartikel
16, 7 (2015)
Identification of novel fusion genes in lung cancer using breakpoint assembly of transcriptome sequencing data. Genome Biology 2014
Zeitschriftenartikel
4 (4), S. 415 - 422 (2014)
CD74-NRG1 fusions in lung adenocarcinoma. Cancer Discovery 2013
Zeitschriftenartikel
123 (4), S. 1732 - 1740 (2013)
Tumor vegf:vegfr2 autocrine feed-forward loop triggers angiogenesis in lung cancer. Journal of Clinical Investigation 2012
Zeitschriftenartikel
18 (17), S. 4682 - 4690 (2012)
Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants. Clinical Cancer Research
Zeitschriftenartikel
44 (10), S. 1104- - 11xx (2012)
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nature Genetics
Zeitschriftenartikel
109 (42), S. 17034 - 17039 (2012)
A framework for identification of actionable cancer genome dependencies in small cell lung cancer. Proceedings of the National Academy of Sciences of the United States of America 2011
Zeitschriftenartikel
1 (1), S. 78 - 89 (2011)
Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discovery
Zeitschriftenartikel
17 (23), S. 7394 - 7401 (2011)
ALK mutations conferring differential resistance to structurally diverse ALK inhibitors. Clinical Cancer Research 2010
Zeitschriftenartikel
5 (1), S. e8919 - e8919 (2010)
Analysis of compound synergy in high-throughput cellular screens by population-based lifetime modeling. PLoS ONE
Zeitschriftenartikel
70 (3), S. 868 - 874 (2010)
Chemogenomic profiling provides insights into the limited activity of irreversible EGFR inhibitors in tumor cells expressing the T790M EGFR resistance mutation. Cancer Research
Zeitschriftenartikel
2 (62), S. 62ra93 - 62ra93 (2010)
Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Science Translational Medicine 2009
Zeitschriftenartikel
106, S. 18351 - 18356 (2009)
Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. Proceedings of the National Academy of Sciences of the United States of America
Zeitschriftenartikel
119 (6), S. 1727 - 1740 (2009)
Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. Journal of Clinical Investigation
Zeitschriftenartikel
69 (8), S. 3256 - 3261 (2009)
PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Research 2008
Zeitschriftenartikel
3 (12), S. e3908 - e3908 (2008)
Early detection of erlotinib treatment response in NSCLC by 3'-Deoxy-3'-[18F]-fluoro-L-thymidine ([18F]FLT) positron emission tomography (PET). PLoS ONE